Moderna reaffirms FY2023 COVID-19 vaccine revenue guidance of $6-8B; provides scenario-based range

Moderna, Inc.

2023-Q3 EPS reported -$12.89 revenue$4,037,000,000

Full-year 2023 COVID-19 vaccine revenue guidance unchanged at $6B-$8B.
If U.S. market is ~50M doses, expects to be in bottom half of range.
If U.S. market is ~100M doses, expects to be in top half of range.
Too early to project; better visibility after October vaccination trends.
Will provide an update at the November 2 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.